Literature DB >> 20848459

Risk factors for metabolic bone disease in Crohn's disease patients.

Marília Cravo1, Catarina Sousa Guerreiro, Paula Moura dos Santos, Miguel Brito, Paula Ferreira, Catarina Fidalgo, Lourdes Tavares, António Dias Pereira.   

Abstract

BACKGROUND: The aim was to evaluate the presence of metabolic bone disease (MBD) in patients with Crohn's disease (CD) and to identify potential etiologic factors.
METHODS: The case-control study included 99 patients with CD and 56 controls with a similar age and gender distribution. Both groups had dual-energy x-ray absorptionmetry and a nutritional evaluation. Single nucleotide polymorphisms at the IL1, TNF-α, LTα, and IL-6 genes were analyzed in patients only. Statistical analysis was performed using SPSS software.
RESULTS: The prevalence of MBD was significantly higher in patients (P = 0.006). CD patients with osteoporosis were older (P < 0.005), small bowel involvement and surgical resections were more frequent (P < 0.005), they more often exhibited a penetrating or stricturing phenotype (P < 0.05), duration of disease over 15 years (P < 0.005), and body mass index (BMI) under 18.5 kg/m(2) (P < 0.01) were more often found. No association was found with steroid use. Patients with a Z-score < -2.0 more frequently had chronic active disease (P < 0.05). With regard to diet, low vitamin K intake was more frequent (P = 0.03) and intake of total, monounsaturated, and polyunsaturated fat was higher in patients with Z-score < -2.0 (P < 0.05). With respect to genetics, carriage of the polymorphic allele for LTα252 A/G was associated with a higher risk of osteoporosis (P = 0.02). Regression analysis showed that age over 40 years, chronic active disease, and previous colonic resections were independently associated with the risk of developing MBD.
CONCLUSIONS: The prevalence of MBD was significantly higher in CD patients. Besides the usual risk factors, we observed that factors related to chronic active and long-lasting disease increased the risk of MBD.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848459     DOI: 10.1002/ibd.21297

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  9 in total

1.  Nutritional management of Crohn's disease.

Authors:  Clare F Donnellan; Lee H Yann; Simon Lal
Journal:  Therap Adv Gastroenterol       Date:  2013-05       Impact factor: 4.409

2.  Bone mineral density and inflammatory bowel disease severity.

Authors:  C A Lima; A C Lyra; C M C Mendes; M B Lopes; F G Coqueiro; R Rocha; G O Santana
Journal:  Braz J Med Biol Res       Date:  2017-10-19       Impact factor: 2.590

3.  Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis.

Authors:  Yuan Feng; Yan Liao; Weijun Huang; Xingqiang Lai; Jing Luo; Cong Du; Junyi Lin; Zhongyuan Zhang; Dongbo Qiu; Qiuli Liu; Huiyong Shen; Andy Peng Xiang; Qi Zhang
Journal:  Cell Death Dis       Date:  2018-06-07       Impact factor: 8.469

4.  What nutritional factors influence bone mineral density in Crohn's disease patients?

Authors:  Fernanda Gomes Coqueiro; Raquel Rocha; Camilla Almeida Menezes; Mirella Brasil Lopes; Vanessa Rosa Oliveira; Flora Maria Lorenzo Fortes; Genoile Oliveira Santana
Journal:  Intest Res       Date:  2018-07-27

Review 5.  Bone alterations in inflammatory bowel diseases.

Authors:  Dolores Sgambato; Francesca Gimigliano; Cristiana De Musis; Antimo Moretti; Giuseppe Toro; Emanuele Ferrante; Agnese Miranda; Domenico De Mauro; Lorenzo Romano; Giovanni Iolascon; Marco Romano
Journal:  World J Clin Cases       Date:  2019-08-06       Impact factor: 1.337

6.  Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease.

Authors:  Benjamin Langan Gordon; Jonathan S Galati; Stevie Yang; Randy S Longman; Dana Lukin; Ellen J Scherl; Robert Battat
Journal:  World J Gastroenterol       Date:  2022-09-07       Impact factor: 5.374

7.  Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease.

Authors:  Carsten Posovszky; Veronika Pfalzer; Georgia Lahr; Jan Hendrik Niess; Jochen Klaus; Benjamin Mayer; Klaus-Michael Debatin; Georg B T von Boyen
Journal:  BMC Gastroenterol       Date:  2013-05-02       Impact factor: 3.067

Review 8.  Body Mass Index Is Associated with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Jie Dong; Yi Chen; Yuchen Tang; Fei Xu; Chaohui Yu; Youming Li; Prasoon Pankaj; Ning Dai
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

9.  Lean mass, magnesium, faecal calprotectin and glucocorticoid exposure as risk factors for low bone mineral density in inflammatory bowel disease patients.

Authors:  Iulia Soare; Anca Sirbu; Mihai Mircea Diculescu; Bogdan Radu Mateescu; Cristian Tieranu; Sorina Martin; Carmen Gabriela Barbu; Mirela Ionescu; Simona Fica
Journal:  Endocr Connect       Date:  2021-08-09       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.